Literature DB >> 8574335

Changes in immunoreactive insulin, C-peptide immunoreactivity, and immunoreactive glucagon in acute viral hepatitis.

K Kaneko1, M Arai, H Funatomi, Y Hatta, K Mitamura.   

Abstract

Insulin and glucagon are thought to play important roles as hepatotrophic factors in acute viral hepatitis (AVH); however, few reports have investigated the responses and relationships of each of these hormones to liver damage in detail. We studied insulin and glucagon responses during the acute and recovery phases of AVH. We performed a glucose tolerance test (GTT) and an insulin sensitivity test (IST) in each phase in 11 patients with AVH. In 8 additional patients in the acute phase (total n = 19), were compared immunoreactive insulin (IRI) and C-peptide immunoreactivity (CPR) levels with transaminase levels. In the acute phase, IRI concentrations were normal from fasting to 60 min, despite an increased CPR level. In the recovery phase, IRI and CPR levels increased significantly. Immunoreactive glucagon levels in both phases did not differ significantly from those in controls. During the IST, the insulin sensitivity index in both phases was significantly lower than that in the controls. Fasting IRI and sigma IRI showed significant negative correlations with transaminase levels. We found enhanced insulin secretion and a decrease in plasma insulin in the acute phase of AVH. The discrepancy between IRI and CPR responses in the acute phase suggests an increase in the degradation or consumption of insulin in the liver.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8574335     DOI: 10.1007/bf02367789

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  29 in total

1.  Insulin and glucagon concentrations in portal and peripheral veins in patients with hepatic cirrhosis.

Authors:  A V Greco; F Crucitti; G Ghirlanda; R Manna; L Altomonte; A G Rebuzzi; A Bertoli
Journal:  Diabetologia       Date:  1979-07       Impact factor: 10.122

2.  Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and I.V. glucose.

Authors:  A V Greco; G Ghirlanda; C Patrono; G Fedili; R Manna
Journal:  Acta Diabetol Lat       Date:  1974 Jul-Aug

3.  C-peptide metabolism and the liver.

Authors:  C Kühl; O K Faber; P Hornnes; S L Jensen
Journal:  Diabetes       Date:  1978       Impact factor: 9.461

4.  Hyperglucagonemia in cirrhosis: altered secretion and sensitivity to glucagon.

Authors:  R S Sherwin; M Fisher; J Bessoff; N Snyder; R Hendler; H O Conn; P Felig
Journal:  Gastroenterology       Date:  1978-06       Impact factor: 22.682

5.  Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture.

Authors:  J R Gavin; J Roth; D M Neville; P de Meyts; D N Buell
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

6.  Insulin resistance in liver cirrhosis: decreased insulin binding to circulating monocytes.

Authors:  A V Greco; A Bertoli; G Ghirlanda; R Manna; L Altomonte; A G Rebuzzi
Journal:  Horm Metab Res       Date:  1980-11       Impact factor: 2.936

7.  Effects of epidermal growth factor/urogastrone and associated pancreatic hormones on mitotic cycle phases and proliferation kinetics of neonatal rat hepatocytes in primary culture.

Authors:  P G Andreis; U Armato
Journal:  Endocrinology       Date:  1981-05       Impact factor: 4.736

8.  Hormonal stimulation of DNA synthesis in primary cultures of adult rat hepatocytes.

Authors:  R A Richman; T H Claus; S J Pilkis; D L Friedman
Journal:  Proc Natl Acad Sci U S A       Date:  1976-10       Impact factor: 11.205

9.  Hyperinsulinism of hepatic cirrhosis: Diminished degradation or hypersecretion?

Authors:  D G Johnson; K G Alberti; O K Faber; C Binder
Journal:  Lancet       Date:  1977-01-01       Impact factor: 79.321

10.  Insulin resistance and insulin receptors in hepatic cirrhosis.

Authors:  A T Blei; D C Robbins; E Drobny; G Baumann; A H Rubenstein
Journal:  Gastroenterology       Date:  1982-12       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.